PE20030730A1 - Comprimido de nelfinavir de dosis incrementada y metodo para fabricarlo - Google Patents
Comprimido de nelfinavir de dosis incrementada y metodo para fabricarloInfo
- Publication number
- PE20030730A1 PE20030730A1 PE2003000074A PE2003000074A PE20030730A1 PE 20030730 A1 PE20030730 A1 PE 20030730A1 PE 2003000074 A PE2003000074 A PE 2003000074A PE 2003000074 A PE2003000074 A PE 2003000074A PE 20030730 A1 PE20030730 A1 PE 20030730A1
- Authority
- PE
- Peru
- Prior art keywords
- nelfinavir
- tablet
- weight
- granulated
- mixture
- Prior art date
Links
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 title abstract 4
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 title abstract 4
- 229960000884 nelfinavir Drugs 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 6
- -1 1,1-DIMETHYLETHYL Chemical class 0.000 abstract 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229960000913 crospovidone Drugs 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- NQHXCOAXSHGTIA-SKXNDZRYSA-N nelfinavir mesylate Chemical compound CS(O)(=O)=O.CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 NQHXCOAXSHGTIA-SKXNDZRYSA-N 0.000 abstract 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 abstract 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 235000012239 silicon dioxide Nutrition 0.000 abstract 1
- 239000000377 silicon dioxide Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Glanulating (AREA)
Abstract
COMPRIMIDO QUE COMPRENDE: i)UN COMPUESTO DE NELFINAVIR (1,1-DIMETILETIL)DECAHIDRO-2-[2-HIDROXI-3-[(3-HIDROXI-2-METILBENZOIL)AMINO]-4-(FENIL-TIO-BUTIL)]-3-ISOQUINOLINACARBOXAMIDA) O UNA SAL FAMACEUTICAMENTE ACEPTABLE COMO MESILATO DE NELFINAVIR PRESENTE EN CANTIDAD SUFICIENTE PARA PROPORCIONAR UNA DOSIS DE NELFINAVIR EQUIVALENTE A 625 mg DE BASE LIBRE DEL MISMO; ii)UN AGLUTINANTE; iii)UN EXCIPIENTE SELECCIONADO DE: 15% A 20% DE CROSPOVIDONA; 0,1% A 0,5% EN PESO DE DIOXIDO DE SILICIO; Y 0,5% A 1,5%, EN PESO DE ESTEARATO DE MAGNESIO; Y, iv)UN RECUBRIMIENTO. DONDE LA RELACION EN PESO DE (i) A (ii) ES APROXIMADAMENTE ENTRE 3:1 Y 5:1. SE REFIERE TAMBIEN A UN METODO PARA FABRICAR UN COMPRIMIDO DE NELFINAVIR QUE COMPRENDE: 1)FORMAR UNA MEZCLA GRANULADA DE (i) Y (ii) EN UN PROCEDIMIENTO DE GRANULACION QUE COMPRENDE: a)ANADIR HUMEDAD Y APLICAR ENERGIA MECANICA A LA MEZCLA; b)CURAR DICHA MEZCLA AL MENOS EN UNA ETAPA DE CURADO SIN ANADIR HUMEDAD NI APLICAR ENERGIA MECANICA; 2)ELABORAR LA MEZCLA GRANULADA PARA FORMAR EL COMPRIMIDO; 3)SECAR LA MEZCLA GRANULADA A UNA TEMPERATURA ENTRE 60 °C Y 80 °C; Y, 4)AGREGAR UN EXCIPIENTE A LA MEZCLA GRANULADA Y MEZCLAR
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35142002P | 2002-01-28 | 2002-01-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030730A1 true PE20030730A1 (es) | 2003-08-28 |
Family
ID=27663002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003000074A PE20030730A1 (es) | 2002-01-28 | 2003-01-24 | Comprimido de nelfinavir de dosis incrementada y metodo para fabricarlo |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP1469836A1 (es) |
| JP (1) | JP2005521661A (es) |
| KR (1) | KR20040079952A (es) |
| CN (1) | CN1713895A (es) |
| AR (1) | AR038236A1 (es) |
| BR (1) | BR0307190A (es) |
| CA (1) | CA2398226A1 (es) |
| GT (1) | GT200300016A (es) |
| HN (1) | HN2003000048A (es) |
| HU (1) | HUP0500512A2 (es) |
| IL (1) | IL162724A0 (es) |
| MX (1) | MXPA04007237A (es) |
| NI (1) | NI200300001A (es) |
| NO (1) | NO20043238L (es) |
| NZ (1) | NZ533283A (es) |
| PA (1) | PA8564301A1 (es) |
| PE (1) | PE20030730A1 (es) |
| PL (1) | PL373882A1 (es) |
| RU (1) | RU2004123206A (es) |
| SV (1) | SV2004001467A (es) |
| TW (1) | TW200302111A (es) |
| WO (1) | WO2003063837A1 (es) |
| ZA (1) | ZA200404367B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008053276A1 (en) * | 2006-10-30 | 2008-05-08 | Collette Nv | Transition piece for the transfer of powder or granular material from a discharge opening to a conveying line and method of transferring powder or granular material |
| US20100262679A1 (en) * | 2007-09-03 | 2010-10-14 | Jim Liu | Method and system for checking automatically connectivity status of an ip link on ip network |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6499984B1 (en) * | 2000-05-22 | 2002-12-31 | Warner-Lambert Company | Continuous production of pharmaceutical granulation |
| EP1390063B1 (en) * | 2001-05-03 | 2004-11-17 | F. Hoffmann-La Roche Ag | Pharmaceutical dosage form of amorphous nelfinavir mesylate |
-
2002
- 2002-08-15 CA CA002398226A patent/CA2398226A1/en not_active Abandoned
-
2003
- 2003-01-07 NI NI200300001A patent/NI200300001A/es unknown
- 2003-01-16 HU HU0500512A patent/HUP0500512A2/hu unknown
- 2003-01-16 NZ NZ533283A patent/NZ533283A/en unknown
- 2003-01-16 WO PCT/IB2003/000117 patent/WO2003063837A1/en not_active Ceased
- 2003-01-16 CN CNA038028360A patent/CN1713895A/zh active Pending
- 2003-01-16 PL PL03373882A patent/PL373882A1/xx not_active Application Discontinuation
- 2003-01-16 EP EP03700070A patent/EP1469836A1/en not_active Withdrawn
- 2003-01-16 JP JP2003563531A patent/JP2005521661A/ja active Pending
- 2003-01-16 KR KR10-2004-7011562A patent/KR20040079952A/ko not_active Ceased
- 2003-01-16 IL IL16272403A patent/IL162724A0/xx unknown
- 2003-01-16 BR BR0307190-1A patent/BR0307190A/pt not_active IP Right Cessation
- 2003-01-16 RU RU2004123206/15A patent/RU2004123206A/ru not_active Application Discontinuation
- 2003-01-16 MX MXPA04007237A patent/MXPA04007237A/es unknown
- 2003-01-24 PE PE2003000074A patent/PE20030730A1/es not_active Application Discontinuation
- 2003-01-27 AR ARP030100228A patent/AR038236A1/es unknown
- 2003-01-27 HN HN2003000048A patent/HN2003000048A/es unknown
- 2003-01-27 SV SV2003001467A patent/SV2004001467A/es not_active Application Discontinuation
- 2003-01-27 TW TW092101739A patent/TW200302111A/zh unknown
- 2003-01-28 GT GT200300016A patent/GT200300016A/es unknown
- 2003-01-28 PA PA20038564301A patent/PA8564301A1/es unknown
-
2004
- 2004-06-03 ZA ZA200404367A patent/ZA200404367B/en unknown
- 2004-08-02 NO NO20043238A patent/NO20043238L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1469836A1 (en) | 2004-10-27 |
| CA2398226A1 (en) | 2003-07-28 |
| NZ533283A (en) | 2006-12-22 |
| MXPA04007237A (es) | 2004-10-29 |
| IL162724A0 (en) | 2005-11-20 |
| NI200300001A (es) | 2004-12-21 |
| TW200302111A (en) | 2003-08-01 |
| ZA200404367B (en) | 2006-05-31 |
| WO2003063837A1 (en) | 2003-08-07 |
| KR20040079952A (ko) | 2004-09-16 |
| HUP0500512A2 (hu) | 2005-09-28 |
| PA8564301A1 (es) | 2003-09-05 |
| CN1713895A (zh) | 2005-12-28 |
| NO20043238L (no) | 2004-08-02 |
| AR038236A1 (es) | 2005-01-05 |
| RU2004123206A (ru) | 2005-04-20 |
| PL373882A1 (en) | 2005-09-19 |
| GT200300016A (es) | 2003-09-11 |
| SV2004001467A (es) | 2004-05-07 |
| BR0307190A (pt) | 2004-11-03 |
| JP2005521661A (ja) | 2005-07-21 |
| HN2003000048A (es) | 2003-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR134222A2 (es) | Un proceso para preparar una composición de comprimido adecuada para el tratamiento de trastornos mediados por la actividad de la tirosina cinasa de bruton | |
| CL2022002695A1 (es) | Inhibidores de rip1k | |
| AR036813A1 (es) | Composiciones farmaceuticas | |
| MX2021006421A (es) | Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17). | |
| AR052878A1 (es) | Formulacion de compresion directa y proceso | |
| AR049000A1 (es) | Formulacion para compresion directa y proceso para la preparacion de una tableta directamente comprimida | |
| MX2022005509A (es) | Compuestos inhibidores de rip1 heterociclicos. | |
| BRPI0510909A2 (pt) | composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor | |
| PE20140960A1 (es) | Formulaciones que comprenden un inhibidor de dpp4 | |
| GT200400239A (es) | Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente | |
| NO20084826L (no) | Ny administrasjonsform av racecadotril | |
| AR054234A1 (es) | Composicion farmaceutica para el tratamiento del cancer | |
| AR111570A1 (es) | Composición farmacéutica que comprende selexipag | |
| PA8616201A1 (es) | Composiciones farmaceuticas de liberacion sostenida | |
| CY1118180T1 (el) | Μεθοδος για παρασκευη στερεας φαρμακευτικης συνθεσης | |
| ECSP034826A (es) | Método para fabricar una composición farmacéutica de dosis baja | |
| MX2022012575A (es) | Compuestos para usarse para tratar la enfermedad de huntington. | |
| CL2022003812A1 (es) | Inhibidores de rip1k | |
| MX2022004882A (es) | Composicion farmaceutica que comprende selexipag. | |
| AR095159A2 (es) | Una composición farmacéutica en forma de cápsula para administración oral | |
| UY27727A1 (es) | Nueva composicion farmacéutica- | |
| PE20030730A1 (es) | Comprimido de nelfinavir de dosis incrementada y metodo para fabricarlo | |
| MXPA02010828A (es) | Composicion farmaceutica en capsulas que comprende un antiinflamatorio no esteroideo y un analgesico opiaceo para el manejo del dolor. | |
| MX2023014898A (es) | Terapia combinada anti-vhc ventajosa. | |
| EA200700203A1 (ru) | Фармацевтическая композиция, содержащая габапентин |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |